|
1）Taguchi K, Motohashi H, Yamamoto M. Molecular mechanisms of the Keap1-Nrf2 pathway in stress response and cancer evolution. Genes Cells. 2011; 16: 123-40
|
|
|
|
2）Wakabayashi N, Itoh K, Wakabayashi J, et al. Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation. Nat Genet. 2003; 35: 238-45
|
|
|
|
|
|
3）Kobayashi A, Kang MI, Okawa H, et al. Oxidative stress sensor Keap1 functions as an adaptor for Cul3-based E3 ligase to regulate proteasomal degradation of Nrf2. Mol Cell Biol. 2004; 24: 7130-9
|
|
|
|
|
|
4）Itoh K, Chiba T, Takahashi S, et al. An Nrf2/small Maf heterodimer mediates the induction of phase II detoxifying enzyme genes through antioxidant response elements. Biochem Biophys Res Commun. 1997; 236: 313-22
|
|
|
|
|
|
5）Mitsuishi Y, Motohashi H, Yamamoto M. The Keap1-Nrf2 system in cancers: stress response and anabolic metabolism. Front Oncol. 2012; 2: 200
|
|
|
|
|
|
6）Kandoth C, McLellan MD, Vandin F, et al. Mutational landscape and significance across 12 major cancer types. Nature. 2013; 502: 333-9
|
|
|
|
|
|
7）Hast BE, Cloer EW, Goldfarb D, et al. Cancer-derived mutations in KEAP1 impair NRF2 degradation but not ubiquitination. Cancer Res. 2014; 74: 808-17
|
|
|
|
|
|
8）Ooi A, Dykema K, Ansari A, et al. CUL3 and NRF2 mutations confer an NRF2 activation phenotype in a sporadic form of papillary renal cell carcinoma. Cancer Res. 2013; 73: 2044-51
|
|
|
|
|
|
9）DeNicola GM, Karreth FA, Humpton TJ, et al. Oncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis. Nature. 2011; 475: 106-9
|
|
|
|
|
|
10）Singh A, Misra V, Thimmulappa RK, et al. Dysfunctional KEAP1-NRF2 interaction in non-small-cell lung cancer. PLoS Med. 2006; 3: e420
|
|
|
|
|
|
11）Network CGAR. Comprehensive genomic characterization of squamous cell lung cancers. Nature. 2012; 489: 519-25
|
|
|
|
|
|
12）Kim Y, Hammerman PS, Kim J, et al. Integrative and comparative genomic analysis of lung squamous cell carcinomas in East Asian patients. J Clin Oncol. 2014; 32: 121-8
|
|
|
|
|
|
13）Stransky N, Egloff AM, Tward AD, et al. The mutational landscape of head and neck squamous cell carcinoma. Science. 2011; 333: 1157-60
|
|
|
|
|
|
14）Network CGAR. Comprehensive molecular profiling of lung adenocarcinoma. Nature. 2014; 511: 543-50
|
|
|
|
|
|
15）Imielinski M, Berger AH, Hammerman PS, et al. Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell. 2012; 150: 1107-20
|
|
|
|
|
|
16）Zhang P, Singh A, Yegnasubramanian S, et al. Loss of Kelch-like ECH-associated protein 1 function in prostate cancer cells causes chemoresistance and radioresistance and promotes tumor growth. Mol Cancer Ther. 2010; 9: 336-46
|
|
|
|
|
|
17）Mitsuishi Y, Taguchi K, Kawatani Y, et al. Nrf2 redirects glucose and glutamine into anabolic pathways in metabolic reprogramming. Cancer Cell. 2012; 22: 66-79
|
|
|
|
|
|
18）Taguchi K, Maher JM, Suzuki T, et al. Genetic analysis of cytoprotective functions supported by graded expression of Keap1. Mol Cell Biol. 2010; 30: 3016-26
|
|
|
|
|
|
19）Shibata T, Saito S, Kokubu A, et al. Global downstream pathway analysis reveals a dependence of oncogenic NF-E2-related factor 2 mutation on the mTOR growth signaling pathway. Cancer Res. 2010; 70: 9095-105
|
|
|
|
|
|
20）Pergola PE, Raskin P, Toto RD, et al. Bardoxolone methyl and kidney function in CKD with type 2 diabetes. N Engl J Med. 2011; 365: 327-36
|
|
|
|
|
|
21）de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013; 369: 2492-503
|
|
|
|
|
|
22）Kensler TW, Egner PA, Agyeman AS, et al. Keap1-Nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem. 2013; 329: 163-77
|
|
|
|
|